CONSIDERATIONS ABOUT NON-PSYCHOTROPIC CANNABINOIDS AND THEIR POTENTIAL APPLICATIONS

Abstract

Non-psychotropic cannabinoids, as well as psychotropic cannabinoids, extracts of Cannabis sativa L. and derived products containing cannabinoids have gained the status of novel foods within the European Union/EU, starting January 2019, thus requiring authorization for the placing on the EU market. With this status comes also the consolidation of an emerging market. At the same time, it should be noted that cannabinoids have already been the object of research, study and applications, for at least decades of modern science, showing comprehensive and extraordinary properties for use as therapeutic agents. The purpose of present paper is to provide an overview of the main non-psychotropic cannabinoids and their pharmacological profiles, with the aim of advocating further research into their potential for various applications, mainly as therapeutic agents, and most importantly with the aim of advocating for pursuing the innovation process all the way to the market uptake of related innovative products.